BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35427999)

  • 1. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.
    Fabris M; De Marchi G; Domenis R; Caponnetto F; Guella S; Dal Secco C; Cabas N; De Vita S; Beltrami AP; Curcio F; Quartuccio L
    J Autoimmun; 2022 May; 129():102827. PubMed ID: 35427999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
    Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
    Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained cell-mediated but not humoral responses in rituximab-treated rheumatic patients after vaccination against SARS-CoV-2.
    Thomas Κ; Grigoropoulos I; Alexopoulou P; Karofylakis E; Galani I; Papadopoulou KK; Tsiavou A; Ntourou A; Mavrou E; Qevani I; Katsimbri P; Koutsianas C; Mavrea E; Vassilopoulos D; Pournaras S; Tsiodras S; Boumpas D; Antoniadou A
    Rheumatology (Oxford); 2024 Feb; 63(2):534-541. PubMed ID: 37228039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
    Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
    Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
    Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
    Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
    Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
    Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.
    Avouac J; Miceli-Richard C; Combier A; Steelandt A; Fogel O; Mariaggi AA; Meritet JF; Rozenberg F; Molto A; Allanore Y
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI163-SI168. PubMed ID: 34726701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters.
    Magliulo D; Wade SD; Kyttaris VC
    Clin Immunol; 2022 Jan; 234():108897. PubMed ID: 34848357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).
    Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J
    Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent but atypical germinal center reaction among 3
    Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Chen Y; Meisel C; Jahrsdörfer B; Ludwig C; Schrezenmeier H; Lino AC; Dörner T
    Front Immunol; 2022; 13():943476. PubMed ID: 36032111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases.
    Oliosi E; Flahault A; Charre C; Veyer D; Combier A; Lafont E; Karras A; Mouthon L; Avouac J; Terrier B; Hadjadj J
    Clin Rheumatol; 2023 Sep; 42(9):2485-2490. PubMed ID: 37243801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of factors involved in the development of humoral response to vaccination against SARS-CoV-2 in patients with rheumatic pathology under biological treatment.
    Flores-Fernández E; Vázquez-Gomez I; Valls-Pascual E; Valera-Ribera C; Andújar-Brazal P; Alegre-Sancho JJ
    Reumatol Clin (Engl Ed); 2023 Dec; 19(10):565-570. PubMed ID: 38008603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.
    Bitoun S; Henry J; Desjardins D; Vauloup-Fellous C; Dib N; Belkhir R; Mouna L; Joly C; Bitu M; Ly B; Pascaud J; Seror R; Roque Afonso AM; Le Grand R; Mariette X
    Arthritis Rheumatol; 2022 Jun; 74(6):927-933. PubMed ID: 34962357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab.
    Tolf A; Wiberg A; Müller M; Nazir FH; Pavlovic I; Laurén I; Mangsbo S; Burman J
    JAMA Netw Open; 2022 May; 5(5):e2211497. PubMed ID: 35544139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab.
    Schultz K; Jannat-Khah D; Spiera R
    J Rheumatol; 2023 Mar; 50(3):420-425. PubMed ID: 36521910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab.
    Jinich S; Schultz K; Jannat-Khah D; Spiera R
    Arthritis Rheumatol; 2022 May; 74(5):776-782. PubMed ID: 34908241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
    Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
    BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
    Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
    Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.
    Troldborg A; Thomsen MK; Bartels LE; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Mikkelsen S; Erikstrup C; Hauge EM; Ammitzbøll C
    J Rheumatol; 2022 Jun; 49(6):644-649. PubMed ID: 35232803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.